New Drug Approvals

Pfizer’s Fosdagrocorat, PF-04171327 for Rheumatoid Arthritis February 15, 2016 - (0)

Fosdagrocorat, PF-04171327, CAS 1044535-58-1 (2R,4aS,10aR)-4a-Benzyl-7-((2-methylpyridin-3-yl)carbamoyl)-2-(trifluoromethyl)-1,2,3,4,4a,9,10,10a-octahydrophenanthren-2-yl dihydrogen phosphate 2-Phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-N-(2-methyl-3-pyridinyl)-4b-(phenylmethyl)-7-(phosphonooxy)-7-(trifluoromethyl)-, (4bS,7R,8aR)- (2R,4aS,10aR)-4a-benzyl-7-((2-methylpyridin-3-yl)carbamoyl)-2-(trifluoromethyl)-1,2,3,4,4a,9,10,10a-octahydrophenanthren-2-yl dihydrogen phosphate MF C29H30F3N2O5P Exact Mass: 574.1844 PF 04171327 PF-04171327 UNII-HPI19004QS Selective Glucocorticoid Receptor Modulator phase 2 .Rheumatoid Arthritis Glucocorticoid receptor modulators Pfizer 03 Sep 2015Phase II development of fosdagrocorat is ongoing 01 Jun 2014Pfizer completes a phase II trial in Rheumatoid arthritis in US, […]
Cipla, New Patent, WO 2016020664, Everolimus February 15, 2016 - (0)
Zydus Cadila, New Patent,US 20160039759, PERAMPANEL February 15, 2016 - (0)
Benfotiamine, бенфотиамин , بينفوتيامين , 苯磷硫胺 , ベンフォチアミン February 14, 2016 - (0)
MELOXICAM February 12, 2016 - (0)

Mobile Site | Full Site